Australian company Radiopharm Theranostics (ASX:RAD) has been granted Human Research Ethics Committee approval to commence its first-in-human Phase I study in Australia for its therapy for patients with PDL1- positive non-small cell lung cancer. …
Radiopharm Theranostics receives approval for study of PDL1-nanobody in lung cancer
October 9, 2023 Australian Biotech
Latest Video
New Stories
-
Finalists named for the 2026 Patient's Choice awards
July 24, 2026 - - Latest News -
Australian company moving headquarters to US and restructuring workforce
July 24, 2026 - - Latest News -
The 'end of days' language is just a farcical attempt to shut down discussion
July 24, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News -
Major brands and biosimilars feature prominently on November PBAC agenda
July 23, 2026 - - Latest News